The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential…

Words Lucie van Leeuwen.Published October 6, 2020
The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.

Update 31-12-2021: Please note that the study is now active and enrolment is completed.

Study Duration

  • 32-36 weeks, including:
  • 4-week screening
  • 24-week study treatment period
  • 4 to 8-week follow-up period

Investigational Drug

  • Tofersen (BIIB067), an antisense oligonucleotide (ASO)
  • Designed to reduce the amount of SOD1 protein in the body
  • Given intrathecally, through a lumbar puncture

Key Eligibility Criteria

  • 18 years of age or older
  • Have weakness caused by ALS
  • Agree to genetic testing for the SOD1 mutation

All Eligible Participants Will Receive At No Cost

  • Comprehensive study-related health evaluations and assessments, including genetic testing
  • Investigational drug or placebo
  • All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view our study locations.


Share

Related news

Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Today, Amylyx Pharmaceuticals provided an update on its plans to advance its […]
Retrotope announces initiation of RT001 study in people with ALS
Retrotope announces initiation of RT001 study in people with ALS
Retrotope Inc has announced that the first participants have been enrolled in […]
Virtual ENCALS meeting 2021
Virtual ENCALS meeting 2021
This year, ENCALS (European Network to Cure ALS) will be organising their […]
New centres in Portugal and Spain join TRICALS network
New centres in Portugal and Spain join TRICALS network
We are very excited to announce that recently two new expert ALS […]